Source: International Journal of Immunopathology and Pharmacology. Unidade: ICB
Assunto: FARMACOLOGIA
ABNT
TZANNO-MARTINS, C. et al. Clinical efficacy, safety and anti-inflammatory activity of two sevelamer tablet forms in patients on low-flux hemodialysis. International Journal of Immunopathology and Pharmacology, v. 27, n. 1, p. 25-35, 2014Tradução . . Acesso em: 16 nov. 2024.APA
Tzanno-Martins, C., Biavo, B. M. M., Ferreira-Filho, O., Ribeiro-Junior, E., João-Luiz, M. V. de S., Degaspari, S., et al. (2014). Clinical efficacy, safety and anti-inflammatory activity of two sevelamer tablet forms in patients on low-flux hemodialysis. International Journal of Immunopathology and Pharmacology, 27( 1), 25-35.NLM
Tzanno-Martins C, Biavo BMM, Ferreira-Filho O, Ribeiro-Junior E, João-Luiz MV de S, Degaspari S, Scavone C, Kawamoto EM. Clinical efficacy, safety and anti-inflammatory activity of two sevelamer tablet forms in patients on low-flux hemodialysis. International Journal of Immunopathology and Pharmacology. 2014 ; 27( 1): 25-35.[citado 2024 nov. 16 ]Vancouver
Tzanno-Martins C, Biavo BMM, Ferreira-Filho O, Ribeiro-Junior E, João-Luiz MV de S, Degaspari S, Scavone C, Kawamoto EM. Clinical efficacy, safety and anti-inflammatory activity of two sevelamer tablet forms in patients on low-flux hemodialysis. International Journal of Immunopathology and Pharmacology. 2014 ; 27( 1): 25-35.[citado 2024 nov. 16 ]